DETERMINANTS OF COMPETITIVENESS IN THE SOUTH AFRICAN AGRO-FOOD AND FIBRE COMPLEX

The competitiveness of the South African agro-food and fibre complex depends on a number of factors: technological, socio-political and economic. This paper attempts to identify and analyse such factors by using a framework of analysis proposed by Michael Porter (1990). Appropriate measures to increase competitiveness are proposed. These include improved supply chain management, cost reduction, contractual pricing and the establishment of a clear "agribusiness development policy".Agribusiness, Industrial Organization,

COMPETING AT THE "CUTTING EDGE": OPPORTUNITIES FOR AGRIBUSINESS PARTNERSHIPS AND CO-OPERATION IN THE SOUTHERN AFRICAN REGION

What are the opportunities for agricultural business, trade and co-operation in Southern Africa and, in particular, South Africa and Zimbabwe - two of the most significant economies in the SADC region? The competitiveness status of agribusiness - from a global viewpoint - in sixteen food and fibre supply chains in Zimbabwe and South Africa is determined in this study using the Revealed Comparative Advantage method of Balassa. Based on this status, there is potential in certain agro-food chains for supply chain integration and cooperation between agribusinesses in South Africa and Zimbabwe. Such partnerships will improve competitiveness and will allow agribusinesses to compete at the "cutting edge" in the global environment.Agribusiness,

TECHNOLOGY, RESEARCH AND DEVELOPMENT AND THE IMPACT ON THE COMPETITIVENESS OF THE SOUTH AFRICAN AGRO-FOOD SUPPLY CHAINS

Industrial Organization, Research and Development/Tech Change/Emerging Technologies,

HOW COMPETITIVE IS AGRIBUSINESS IN THE SOUTH AFRICAN FOOD COMMODITY CHAIN?

The competitiveness of sixteen selected food commodity chains in South Africa was calculated using the Revealed Comparative Advantage method of Balassa. The majority of commodity chains are marginally competitive. Except for the maize, pineapple, and apple chains, the competitiveness index generally decreases when moving from primary to processed products. This implies that benification or "value adding" opportunities in South Africa are restricted. To compete in a global economy strategies should be followed that improve the competitiveness of the whole food supply chain. It is i.e. not good enough for farmers to be able to compete globally at farm gate level, whilst the locally processed commodities that is sold to the consumer is not competitive in the world market.Agribusiness,

ARE WE STILL INVESTING IN SOUTH AFRICAN AGRICULTURE: PERCEPTIONS, EVIDENCE AND ANALYSIS

In this paper the question of investment in the South African agro-food and fibre complex is explored. The analysis is based on empirical values and opinions/perceptions from ±400 agribusinesses operating in this complex. From the analysis it is clear that decisions to invest in the agro-food and fibre complex in South Africa must be viewed as on "knife-edge". A range of recommendations and policy options will be required to activate investment drivers and to address constraints in order to stimulate investment and to achieve growth.Agricultural and Food Policy,

Attitudes and acceptance of South African urban consumers towards genetically modified white maize

The introduction of genetically modified (GM) food products to food markets around the world, has led to considerable controversy. In many cases consumer attitudes and perceptions of GM food products were revealed as fears, concern for, and avoidance of the new technology. The importance of GM foods in South Africa is increasing, even though the GM Food debate lags behind many other (often more developed) parts of the world. This paper investigates the knowledge, attitudes and acceptance of urban South African white-grain maize consumers regarding GM maize. Conjoint- and cluster analysis were used to develop clusters/market segments among the urban consumers of white maize. A range of additional questions was used to develop profiles of the identified market segments. These aspects covered demographics, GM knowledge aspects as well as GM attitude aspects. Four distinct clusters/market segments were identified with specific characteristics: "Anti-GM, Brand aware" cluster (35% of valid responses), "Brand unaware, Farmer sympathetic" cluster (20%), "GM consumer benefit, Brand aware" cluster (25%) and the "Brand aware, Pro-GM" cluster (20%). The most significant differences between the clusters were based on the consumers' attitudes towards GM food products.Consumer/Household Economics,

Strategic focus areas and emerging trade arrangements in the South African agricultural industry since the demise of the marketing boards

This paper investigates the responses of agribusiness managers to drastic changes in the policy and marketing environment of South African agriculture. The process of deregulation and liberalisation of agricultural markets exposed agribusiness managers to international trends, which required new institutions and relationships. Based on a survey conducted among business managers, we explored emerging growth strategies, strategic focus areas and coordination preferences. Results suggest that managers prefer a growth strategy based on market penetration and market development. Important strategic drivers are value-adding and power drive. Managers expressed their preference for increased coordination and cooperation resulting in relation-based contracts and equity-based alliances.agribusiness, strategic focus areas, institutional arrangements, South Africa, Agribusiness,

Immunodominant T Cell Determinants of Aquaporin-4, the Autoantigen Associated with Neuromyelitis Optica

Autoantibodies that target the water channel aquaporin-4 (AQP4) in neuromyelitis optica (NMO) are IgG1, a T cell-dependent Ig subclass. However, a role for AQP4-specific T cells in this CNS inflammatory disease is not known. To evaluate their potential role in CNS autoimmunity, we have identified and characterized T cells that respond to AQP4 in C57BL/6 and SJL/J mice, two strains that are commonly studied in models of CNS inflammatory diseases. Mice were immunized with either overlapping peptides or intact hAQP4 protein encompassing the entire 323 amino acid sequence. T cell determinants identified from examination of the AQP4 peptide (p) library were located within AQP4 p21-40, p91-110, p101-120, p166-180, p231-250 and p261-280 in C57BL/6 mice, and within p11-30, p21-40, p101-120, p126-140 and p261-280 in SJL/J mice. AQP4-specific T cells were CD4+ and MHC II-restricted. In recall responses to immunization with intact AQP4, T cells responded primarily to p21-40, indicating this region contains the immunodominant T cell epitope(s) for both strains. AQP4 p21-40-primed T cells secreted both IFN-γ and IL-17. The core immunodominant AQP4 21-40 T cell determinant was mapped to residues 24-35 in C57BL/6 mice and 23-35 in SJL/J mice. Our identification of the AQP4 T cell determinants and characterization of its immunodominant determinant should permit investigators to evaluate the role of AQP4-specific T cells in vivo and to develop AQP4-targeted murine NMO models

Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Neuromyelitis optica (NMO) is an autoimmune disease of the CNS that is characterized by inflammatory demyelinating lesions in the spinal cord and optic nerve, potentially leading to paralysis and blindness. NMO can usually be distinguished from multiple sclerosis (MS) on the basis of seropositivity for IgG antibodies against the astrocytic water channel aquaporin-4 (AQP4). Differentiation from MS is crucial, because some MS treatments can exacerbate NMO. NMO pathogenesis involves AQP4-IgG antibody binding to astrocytic AQP4, which causes complement-dependent cytotoxicity and secondary inflammation with granulocyte and macrophage infiltration, blood-brain barrier disruption and oligodendrocyte injury. Current NMO treatments include general immunosuppressive agents, B-cell depletion, and plasma exchange. Therapeutic strategies targeting complement proteins, the IL-6 receptor, neutrophils, eosinophils and CD19--all initially developed for other indications--are under clinical evaluation for repurposing for NMO. Therapies in the preclinical phase include AQP4-blocking antibodies and AQP4-IgG enzymatic inactivation. Additional, albeit currently theoretical, treatment options include reduction of AQP4 expression, disruption of AQP4 orthogonal arrays, enhancement of complement inhibitor expression, restoration of the blood-brain barrier, and induction of immune tolerance. Despite the many therapeutic options in NMO, no controlled clinical trials in patients with this condition have been conducted to date